Compare Ascendis Pharma A/S (ASND) vs DuPont de Nemours Inc (DD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs DuPont de Nemours Inc — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while DuPont de Nemours Inc trades at $144.26 (market cap $19.12B). The key difference: Ascendis Pharma A/S and DuPont de Nemours Inc are close in size by market cap, and DuPont de Nemours Inc pays a 1.7% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | DD | |
|---|---|---|
Market Cap | $16.78B | $19.12B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $154.59 |
52-Week Low | $189.74 | $87.72 |
Enterprise Value | $17.15B | $20.50B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.41, up 2.23% with a bullish technical signal. The company shows strong revenue growth from $364M in 2024 to $720M in 2025, though remains unprofitable with a net loss of $228M. Recent news highlights positive clinical trial results for achondroplasia treatments and inclusion in Russell indexes. Analyst consensus is strongly bullish with 92% buy ratings and a $309.75 price target, representing 21% upside potential.
ASND presents significant growth potential with multiple product launches and expanding rare endocrine franchise, but carries substantial risk due to negative equity, high debt levels, and ongoing losses. The transition to profitability projected for 2026 with $496M net income represents a key inflection point. Investors should weigh the strong analyst optimism against the company's financial leverage and execution risks in drug commercialization.
DuPont (DD) trades at $142.48, down 1.06% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported Q2 2026 earnings that beat expectations, with EPS of $1.88 versus $1.76 expected, and raised its full-year 2026 outlook, driven by healthcare, industrial water, and aerospace demand. However, 2025 fundamentals show a net loss of $779 million on revenue of $6.85 billion, with a high P/E ratio of 61.15 indicating premium valuation.
The outlook is cautiously optimistic, supported by earnings momentum and innovation awards, but risks include ongoing legal settlements over PFAS chemicals and thin net margins. The consensus price target of $232.80 suggests significant upside potential if operational improvements continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →
